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ABSTRACT
Chronic myeloid leukemia (CML) is a myeloprolifera-
tive disorder whose therapy has changed dramatically
since the late 1990s. With the introduction of the tyro-
sine kinase inhibitor (TKI) imatinib mesylate, the treat-
ment outcomes for patients with CML have improved
markedly, and hematopoietic stem-cell transplantation
is no longer routinely offered as first-line therapy for
most patients in chronic phase.
However, resistance to TKI therapy is increasingly
being recognized, and alternative therapy is needed for
this group of patients. In addition, the development of
models predicting response to TKI therapy is desired,
so that appropriate treatment strategies can be used
for individual patients. The present report serves to
outline the approach to the treatment of CML in British
Columbia and to highlight areas of ongoing research.
KEY WORDS
Chronic myeloid leukemia, treatment guidelines
1. INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloprolifera-
tive disorder characterized by the increased prolifera-
tion of myeloid cells at all stages of maturation. The
cytogenetic hallmark of the disease is the presence of
the Philadelphia (Ph) chromosome or its molecular
equivalent (BCR-ABL). The Ph chromosome consists
of a reciprocal translocation between the Ableson onco-
gene (ABL) on chromosome 9 and the breakpoint clus-
ter region (BCR) on chromosome 22, resulting in a
chimeric Bcr-Abl protein with constitutive tyrosine
kinase activity. The protein kinase is instrumental in
the activation of multiple signalling pathways (JAK–
STAT, RAS, and PI3K) affecting cellular proliferation
and apoptosis, leading to a leukemic phenotype.
With the greater understanding of the molecular
biology of CML has come the development of novel
therapies specifically designed to selectively inhibit the
tyrosine kinase activity of Bcr-Abl. Indeed, with the
introduction of such targeted therapy, the therapeutic
options and management strategies for CML have
changed considerably in the last few years. Allogeneic
stem-cell transplantation remains a potentially cura-
tive treatment for selected patients with CML, but the
lack of suitable donors and the associated morbidity
and mortality limits its applicability. The use of tyro-
sine kinase inhibitors (TKIs) in CML has so far demon-
strated impressive results with minimal toxicity and
has thus drastically changed the landscape of CML
therapy. However, the lack of long-term clinical data—
in particular, data relating to survival—has led to an
ongoing controversy about the best therapy for indi-
vidual patients.
The aims of the present report are to outline the
approach to the management of CML in British Co-
lumbia and to discuss the challenges that remain for
future research.
2. DISCUSSION
2.1 Diagnosis and Initial Investigations
At presentation, initial investigations should include a
complete blood count and white blood cell differential;
serum electrolytes, including creatinine; liver function
tests; uric acid; and a bone marrow aspirate and bi-
opsy with cytogenetic analysis. Bone marrow exami-
nation provides valuable information regarding cellu-
lar morphology, marrow cellularity, number of blast
cells, and the presence of fibrosis. Standard karyotyping
is useful to document the presence of the Ph chromo-
some and whether additional chromosomal abnormali-
ties are present at diagnosis, constituting clonal evolu-
tion. Taken together, this information will allow the
patient to be appropriately classified into chronic phase
(CP), accelerated phase (AP), or blast phase (BP), and
to be assigned a Sokal risk score 1.
Further studies that may be useful include fluores-
cent in situ hybridization (FISH), which will detect the
presence or absence of deletions in the derivative 9
chromosome. Such deletions have been associated with
inferior overall survival and progression-free survivalFORREST et al.
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for CP patients treated with interferon alpha 2. Less is
known about the impact of such deletions for patients
receiving imatinib therapy, although preliminary reports
suggest little to no effect on outcome 3,4.
Molecular analysis of the BCR-ABL fusion gene
by polymerase chain reaction (PCR) can also provide
confirmation of the presence of the Ph chromosome,
PCR being associated with a high degree of sensitivity
and specificity. At diagnosis, PCR positivity for BCR-
ABL transcripts on blood or bone marrow can confirm
the diagnosis of CML even in the rare patient that is
Ph-negative by standard karyotyping or FISH analy-
sis. Furthermore, quantitation by PCR of the BCR-ABL
transcripts (QPCR) can provide a baseline measure-
ment for subsequent disease monitoring. The high
degree of sensitivity of QPCR allows for monitoring
of minimal residual disease for patients achieving a
complete cytogenetic response (CCR) to therapy. Be-
cause most CP patients achieve a CCR on imatinib,
QPCR is indispensable as a monitoring strategy in CML.
By virtue of its ability to detect small changes in the
disease burden, it may reveal early signs of emerging
resistance to therapy before a hematologic or cytoge-
netic relapse occurs.
2.2 Prognostic Factors
In the pre-imatinib era, several clinical and laboratory
features were identified that predict response to therapy.
The Sokal score, initially developed to predict response
to busulfan still retains some predictive value with
imatinib therapy 1. Patients with a high-risk Sokal score
have a 69% chance of achieving CCR, as compared
with an 82% chance with an intermediate score or a
98% chance with a low-risk score 5. However, once a
CCR has been achieved, the Sokal score loses its prog-
nostic importance, and progression-free survival for all
three groups remains equivalent. Therefore, even a
high-risk Sokal score at diagnosis does not on its own
seem to justify an alternative front-line therapy with-
out an initial trial of imatinib.
The presence of karyotypic abnormalities at diag-
nosis in addition to the standard Ph chromosome has
also been associated with an adverse prognosis. Clonal
evolution is usually accompanied by other manifesta-
tions of more advanced-phase disease; however, in iso-
lation, clonal evolution may not necessarily be associ-
ated with an inferior outcome on higher-dose imatinib 6.
Furthermore, deletions involving the derivative 9 chro-
mosome determined by FISH analysis are also predic-
tive of poor outcome with interferon-based therapy.
However, the significance of such deletions is less clear
for patients receiving imatinib, and preliminary reports,
at least, suggest little to no effect on outcome 3,4.
These historical clinical and laboratory factors
have limited predictive value for patients now receiv-
ing therapy with imatinib, and “newer” predictive
models are needed. Because much of the biology of
CML, including resistance to TKIs, can be explained
by the biology of the CML stem cells that sustain the
CML clone, examining various aspects of the stem-cell
compartment will hopefully help to determine if any
stem-cell-related factors are predictive of patterns of
failure to TKI therapy (see “Future Strategies,” later in
this article).
2.3 Therapeutic Options and Treatment Algorithms
With the introduction of TKIs (imatinib, dasatinib,
nilotinib), much has changed in the standard approach
to CML therapy. Before imatinib became available, most
CML patients received treatment with interferon alpha,
with or without cytarabine, or alternatively underwent
allogeneic stem-cell transplantation if deemed eligi-
ble with a suitable donor. As compared with hydroxyu-
rea or busulfan, interferon alpha has been shown to
prolong survival; however, only a small proportion of
patients (20%–30%) achieve a major cytogenetic res-
ponse, and the survival benefit is largely limited to such
responders 7,8. Furthermore, interferon is associated
with a number of dose-related toxicities, and most pa-
tients require dose reductions or discontinuation. For
those reasons, interferon therapy has been largely re-
placed by the more effective and less toxic TKIs. In
British Columbia, we have developed treatment algo-
rithms (Figures 1, 2, and 3) that are largely based on
the newly developed TKI therapy.
2.4 Imatinib Mesylate
Imatinib was the first TKI approved in Canada for the
treatment of CML in all phases of disease. The pivotal
clinical trial establishing efficacy for imatinib was the
International Randomized Study of Interferon and
STI571, an open-label phase III randomized study of
1106 patients with newly diagnosed CML in CP 5. After
a median follow-up of 60 months, survival without pro-
gression to AP or BP was 93% for imatinib, and the
estimated rate of CCR was 87%. By contrast, only 3%
of patients initially randomized to interferon and
cytarabine continued on their initial therapy.
Given those excellent results, our approach in Brit-
ish Columbia is to offer imatinib at the recommended
starting dose of 400 mg daily as initial therapy to all
patients newly diagnosed with CML in CP. Patients with
cytogenetic abnormalities in addition to the Ph chro-
mosome at diagnosis (clonal evolution), but with no
other features of AP, are treated with escalated-dose
imatinib (600 mg daily). The rational for escalation is
that, although clonal evolution is usually accompanied
by other features of more advanced disease, clonal
evolution by itself may not necessarily be associated
with an inferior outcome on higher-dose imatinib 6.
The subsequent management of patients on imatinib
is guided by their response to therapy as determined by
hematologic, cytogenetic, and molecular measure-
ments over time (see “Disease Monitoring and Imatinib
Resistance” later in this article).MANAGEMENT OF CML IN BRITISH COLUMBIA
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2.5 Hematopoietic Stem-Cell Transplantation
Allogeneic hematopoietic stem-cell transplantation
(HSCT) remains the only known potentially curative
therapy for CML, and before the introduction of ima-
tinib, HSCT was routinely offered to eligible patients
with suitable donors. Data from the Leukemia/BMT
Program of BC shows that the 7-year event-free sur-
vival for related donor allogeneic transplant in CP is
61% (Figure 4) with a 7-year transplant-related mor-
tality of 29% and a risk of relapse of 14%. Since the
late 1990s, improvements in supportive care have re-
sulted in lower transplant-related mortality and im-
proved outcomes; however, the remaining risks of the
procedure and a lack of suitable donors has in many
cases limited its applicability—at least as initial therapy
for newly diagnosed patients. With availability of TKIs,
the potential toxicity of a transplant must now be bal-
anced with the chance of long-term survival.
With that balance in mind, attempts have been
made to better assess the risks and benefits for pa-
tients eligible for HSCT by developing scoring systems
aimed at predicting transplant outcome for selected
patients 9. However, despite an ability to identify pa-
tients predicted to have a low risk of transplant-related
mortality, an initial trial of imatinib therapy is still jus-
tified for nearly all patients; HSCT is reserved for pa-
tients without a satisfactory response to imatinib the-
rapy. That being said, the final decision concerning
whether to pursue medical management or transplan-
tation should be discussed with each patient at diagno-
sis so that therapy can be appropriately individualized.
In British Columbia, referral to the Leukemia/BMT
Program of BC of every patient considered a potential
FIGURE 1   Treatment algorithm for chronic myeloid leukemia (CML) in chronic (stable) phase (SP). CHR = complete hematologic response; MCR =
major cytogenetic response; Ph+ = positive for the Philadelphia chromosome; BM = bone marrow; FISH = fluorescence in situ hybridization; PB
= peripheral blood; QPCR = quantitative polymerase chain reaction; SD = sibling donor; Dx = diagnosis; q. = every; Allo SCT = allogeneic stem-
cell transplantation; Mud SCT = matched unrelated donor stem-cell transplantation.FORREST et al.
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transplant candidate for a detailed discussion about the
role of transplantation in their management is strongly
encouraged.
2.6 Disease Monitoring and Imatinib Resistance
Once patients have commenced imatinib therapy, our
approach in British Columbia is to document normali-
zation of peripheral blood counts [complete hematologic
response (CHR)], which ideally should occur within 3
months of the start of imatinib therapy. Once CHR has
been obtained, further evaluation of disease response
requires cytogenetic or FISH analysis on bone marrow
samples or, alternatively, QPCR of BCR-ABL on blood
or marrow.
Cytogenetic analysis is labour-intensive, requires
serial bone marrow aspirates, and has limited sensi-
tivity; therefore, in British Columbia, we have elected
to use QPCR to monitor all of our CML patients every
3 months once a CHR has been obtained. This highly
sensitive test is able to detect 1 abnormal Ph+ cell in
10,000 normal cells, and it has the further advantage
of being able to be performed on peripheral blood.
The correlation of peripheral blood QPCR with bone
marrow cytogenetics is excellent and thus provides a
simple, but very sensitive tool to measure minimal
residual disease 10,11. In British Columbia, routine
annual bone marrow tests are no longer recommended,
provided that response to therapy is satisfactory (CHR
by 3 months, >1-log reduction in BCR-ABL by 6–12
months, >2-log reduction in BCR-ABL by 12–18
months; Table I) 12.
For patients who do not achieve those milestones
or who later develop progression (resistance) after an
initial response, a change in therapy is needed. It is
important to note that there is no evidence that TKI
therapy actually “causes” resistant mutant BCR-ABL
cells to arise; rather, the therapy appears to select for
mutants already present. Once resistance (either pri-
mary or acquired) to imatinib has been documented
FIGURE 2   Treatment algorithm for chronic myeloid leukemia (CML) in accelerated phase (AP). BM = bone marrow; FISH = fluorescence in situ
hybridization; PB = peripheral blood; QPCR = quantitative polymerase chain reaction; SCT = stem-cell transplantation; SD = sibling donor; Mud
= matched unrelated donor; Allo = allogeneic; BP = blast phase; CHR = complete hematologic response; MCR = major cytogenetic response.MANAGEMENT OF CML IN BRITISH COLUMBIA
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(Table II), we recommend a bone marrow aspirate and
biopsy with cytogenetic analysis to establish current
disease status and whether evidence of progression to
AP or BP is present. Mutational analysis should also be
undertaken to document the presence or absence of
mutations in the BCR-ABL kinase domain that may
mediate imatinib resistance 13. Finally, a trough serum
imatinib level may also provide useful information 14.
Patients with low serum imatinib levels and inferior
responses may respond to escalated-dose imatinib.
Depending on the results of the foregoing investi-
gations, a change in therapy may be undertaken, which
may include dose escalation of imatinib, a change to
dasatinib, allogeneic HSCT, or enrolment in a clinical
trial.
2.7 Dasatinib
Dasatinib is a dual TKI and Src inhibitor with increased
potency as compared with imatinib. It recently recei-
ved conditional approval from Health Canada for the
treatment of CML (CP, AP, or BP) in patients with re-
sistance or intolerance to imatinib therapy.
Primary resistance (lack of efficacy from the on-
set of therapy) to imatinib is unusual in CP patients, but
acquired resistance resulting from the selection and
expansion of pre-existing mutants can be seen in ap-
proximately 15% of CP patients. Such resistance in-
creases in frequency with more advanced phases of
disease. The most common mechanism of acquired
resistance to imatinib is point mutations in the ABL
kinase domain, interfering with imatinib binding;
however, BCR-ABL genomic amplification and altera-
tion in drug efflux and influx have also been impli-
cated 13. The recent phase II studies of dasatinib therapy
for imatinib-resistant or -intolerant CML patients docu-
mented efficacy in all phases of disease, with an ac-
ceptable side-effect profile 15–17. Based on the results
of those clinical trials, the British Columbia Cancer
Agency recently approved the use of dasatinib for CML
patients (CP, AP, and BP) with documented resistance
or intolerance to imatinib therapy (Table II).
FIGURE 3   Treatment algorithm for chronic myeloid leukemia (CML) in blast phase (BP). VCR = vincristine; DNR = daunorubicin; Pred = prednisone;
SP2 = second stable phase; HIDAC = high-dose cytarabine; SD = sibling donor; Allo = allogeneic; SCT = stem-cell transplantation; Mud = matched
unrelated donor; PB = peripheral blood; QPCR = quantitative polymerase chain reaction.FORREST et al.
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One special group of patients, those harbouring a
T315I mutation in the ABL kinase domain, warrants
further discussion. The T315I mutation has been shown
to mediate resistance to all three TKIs (imatinib,
dasatinib, nilotinib), and therefore patients with this
particular mutation should be evaluated for an alloge-
neic HSCT or offered experimental therapy if trans-
plantation is not a suitable option.
2.8 Nilotinib
Like dasatinib, nilotinib is a new, second-generation TKI
with structural similarity to imatinib. It has greater po-
tency than imatinib, with activity against most imatinib-
resistant BCR-ABL mutations, with the notable excep-
tion of the T315I mutation, in which resistance to TKI
therapy is universal. Results of phase I and II studies
with nilotinib are encouraging, with a CHR of 75% and a
CCR of 40% in CP patients with imatinib resistance or
intolerance 18,19. However, longer follow-up will be
needed to assess whether these responses are durable.
Based on the early results, further clinical trials with
nilotinib are underway, but nilotinib is not currently ap-
proved by Health Canada. Access therefore remains in
the context of clinical trials.
3. FUTURE STRATEGIES
Despite the excellent clinical activity of the TKIs
(imatinib, dasatinib, nilotinib), these drugs are gener-
ally ineffective on the CML stem-cell population, which
includes a significant quiescent component. That par-
ticular cell population is also felt to represent the res-
ervoir from which clinical resistance may develop. As
a consequence of the persistence of CML stem cells,
TKI therapy is not considered curative, and new treat-
ment strategies continue to be explored.
One strategy currently undergoing exploration is
the targeting of molecular pathways activated by the
Bcr-Abl oncoprotein in the CML stem cells. The far-
FIGURE 4   Event-free survival for related-donor stem-cell trans-
plantation in chronic myeloid leukemia (CML) by disease status at 7
years. SP1 = first stable phase; AP = accelerated phase; BP = blast
phase.
TABLE I   Milestone criteria and timelines
Response Duration of therapy
Complete hematologic response         3 months
Major cytogenetic response      6–12 months
Complete cytogenetic response    12–18 months
Major molecular response    18–24 months
TABLE II Resistance and intolerance to imatinib
                                                                                           RESISTANCE
CML chronic phase CML accelerated and blast phases
Lack of complete hematologic response after 3 months a Lack of response after ≥ 4 weeks of imatinib ≥ 600 mg
Lack of any cytogenetic response after 6 months a No complete hematologic response in accelerated phase at 3 months
Lack of major cytogenetic response (or 1-log reduction BCR-ABL) Incomplete response with no further improvement in blast phase
   after 12 months a after 1 month of imatinib ≥ 600 mg daily
Lack of complete cytogenetic response (or 2-log reduction BCR- Cytogenetic relapse (loss of complete cytogenetic response or >2-log
   ABL) after 18 months a     reduction of BCR-ABL,or major cytogenetic response or >1-log
Cytogenetic relapse (loss of complete cytogenetic response or reductionof BCR-ABL,or any Ph+ cell increase ≥ 30%)
   >2-log reduction of BCR-ABL,or major cytogenetic response Loss of complete hematologic response
   or >1-log reduction of BCR-ABL, or any Ph+ cell increase ≥ 30%) Progression of accelerated phase to blast phase or to recurrent blast
Loss of complete hematologic response    phase
Progression to accelerated or blast phase CML for ≥ 4 weeks, unless
   intolerant
                                                                                                  INTOLERANCE
≥ Grade 3 non-hematologic toxicity not responding to symptomatic treatment or dose adjustments of imatinib
Grade 4 hematologic toxicity lasting >7 days
Sustained highly symptomatic grade 2 non-hematologic toxicity
a   Patient should be treated with a minimum of 600 mg imatinib.
CML = chronic myeloid leukemia; Ph+ = positive for the Philadelphia chromosome.MANAGEMENT OF CML IN BRITISH COLUMBIA
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nesyl transferase inhibitors (FTIs) are a new class of
anticancer drugs in this area. These drugs competitively
inhibit the enzyme farnesyl transferase. The potent
cytotoxic FTI BMS-214662 (Bristol–Myers Squibb,
Montreal, QC) has antitumour activity in several tu-
mour models. Recent work by a group at the Univer-
sity of Glasgow has also shown that in vitro treatment
with BMS-214662 results in a significant reduction in
the number of CML stem cells, suggesting a possible
new avenue to treatment.
Approximately 15% of CP patients receiving ima-
tinib will develop resistance, and the frequency increases
(to as high as 40%) in more advanced phases. Identifi-
cation at diagnosis, through new predictive tests, of pa-
tients that are likely to develop TKI resistance so that an
alternative therapy may be contemplated is another im-
portant need. To that end, we are investigating whether
CML stem cells from imatinib non-responders have an
increased inherent imatinib insensitivity or genetic in-
stability that predisposes to the acquisition of BCR-ABL
mutations 20. Our preliminary results suggest that analy-
sis of specific properties of the CML stem cells at diag-
nosis may help to predict individual patient response to
TKI therapy and thus aid in the future development of
more effective treatment algorithms.
All of this research work depends on the provi-
sion of appropriate clinical material to the laboratory,
and as part of our treatment strategy in British Co-
lumbia, all patients with CML are asked to participate
in these efforts by providing blood and marrow sam-
ples at diagnosis once consent has been obtained. Co-
operation of this kind between the patient, the clini-
cian, and the laboratory will help in the ultimate dis-
covery of more effective treatments for all patients
diagnosed with CML.
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